The short version of certificate of analysis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-07 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
==== Rationalizations of traditional medicine ==== It is a generally held belief within the acupuncture community that acupuncture points and meridians structures are special conduits for electrical signals, but no research has established any consistent anatomical structure or function for either acupuncture points or meridians. Human tests to determine whether electrical continuity was significantly different near meridians than other places in the body have been inconclusive. Scientific research has not supported the existence of qi, meridians, or yin and yang. A Nature editorial described TCM as "fraught with pseudoscience", with the majority of its treatments having no logical mechanism of action. Quackwatch states that "TCM theory and practice are not based upon the body of knowledge related to health, disease, and health care that has been widely accepted by the scientific community. TCM practitioners disagree among themselves about how to diagnose patients and which treatments should go with which diagnoses. Even if they could agree, the TCM theories are so nebulous that no amount of scientific study will enable TCM to offer rational care." Academic discussions of acupuncture still make reference to pseudoscientific concepts such as qi and meridians despite the lack of scientific evidence.
Under Bello's direction, SoBe launched a line of "3C" Elixirs (containing calcium, carnitine and chromium) in varieties such as Orange-Carrot, Orange-Tomato (including lycopene), Energy (with guarana, yohimbe and arginine), Power (taurine, creatine and proline), Zen Blend (triple ginseng tea with schizandra), Wisdom (with ginkgo biloba, St. John's wort and gotu kola) and Eros (with dong quai, damiana, foti and zink). Other fun SoBe products included Lizzard Blizzard, Tsunami, Fierce, Courage and Long John Lizard’s Grape Grog. He created the "dueling lizards" design and took a lead role in the company's guerrilla marketing effort, proclaiming himself as the "Lizard King" in radio advertisements. He gave the brand an "attitude" by enlisting athletes who were somewhat out of the mainstream—such as golfer John Daly and downhill skier Bode Miller—as official spokespersons for the brand. The SoBe marketing team also wooed independent beverage distributors, offering them very high margins and a small chunk of equity in the company. From its creation in 1995, SoBe's sales rose rapidly and climbed to $275 million by 2000. The following year, the brand rode the "good-for-you" trend among American consumers to break the quarter billion dollar barrier in 2000. SoBe was sold to PepsiCo for a reported $370 million cash on October 30, 2000. Bello remained with Pepsi overseeing SoBe until early 2004. By the end of 1999 the company had sold 14.8 million cases of drinks and taken in $166.4 million.
Eric Stephen Schmitt (born June 20, 1975) is an American attorney and politician serving since 2023 as the junior United States senator from Missouri. A member of the Republican Party, Schmitt served as the 46th state treasurer of Missouri from 2017 to 2019 and as the 43rd Missouri attorney general from 2019 to 2023. Schmitt began his political career as an alderman for Glendale, Missouri. From 2009 to 2017, he represented the 15th district in the Missouri Senate, during which he sponsored major reductions in the state income tax and franchise tax, and expanded benefits and tax exemptions for disabled citizens. As a state senator, Schmitt also led a bipartisan effort in response to the Ferguson unrest to successfully eliminate traffic ticket quotas and limit local revenues from non-traffic fines. In 2016, Schmitt was elected State Treasurer of Missouri. In 2018, Governor Mike Parson appointed Schmitt Missouri Attorney General. He was elected to a full four-year term as attorney general in 2020. As attorney general, he filed or joined lawsuits seeking to invalidate the Affordable Care Act, challenge the results of the 2020 presidential election (in Texas v. Pennsylvania), and, on 25 occasions, oppose the policies of the Joe Biden administration. He also sued school districts and municipalities for implementing mask requirements during the COVID-19 pandemic and sued the government of China and Chinese Communist Party for their alleged role in the pandemic. In 2022, Schmitt was elected to the U.S. Senate, defeating Democratic nominee Trudy Busch Valentine.
=== 1990s === In the fall of 1990, Kidder appeared as a singer who becomes a murder victim in the Canadian television film White Room (1990). After her car accident, Kidder returned to the screen with an uncredited cameo appearance in the comedy film Delirious (1991), appearing as a woman in a washroom. This was followed by a role as a psychic in To Catch a Killer (1992), a Canadian television thriller film based on the crimes of John Wayne Gacy. She had several small roles in 1994, including in the Disney Channel film Windrunner, as well as another uncredited appearance in Maverick. She played a bartender at the Broken Skull Tavern in Under a Killing Moon, a PC FMV adventure game. Kidder returned to film with a lead role in the independent comedy-drama Never Met Picasso (1997), portraying an actress living with her gay adult son (portrayed by Alexis Arquette), who is attempting to sort his life out. Kevin Thomas of the Los Angeles Times wrote, "Arquette and Kidder [were] given the chance to come across as quite appealing" in their roles. She next appeared in the slasher film The Clown at Midnight (1998), opposite Christopher Plummer, and alongside Lynn Redgrave and James Earl Jones in the romance film The Annihilation of Fish (1999), playing the landlady of an interracial couple. Critic Todd McCarthy in Variety referred to the film as a "would-be charmer" and "a drear moment in the careers of all concerned."
Sources: en.wikipedia.org
=== Peptide === Ghrelin (Lenomorelin, GHRL) GHRP-1 GHRP-2 (Pralmorelin; GHRP Kaken 100; GHRP-2; KP-102, GPA-748, WAY-GPA-748) GHRP-3 GHRP-4 GHRP-5 GHRP-6 (SKF-110679) Alexamorelin Examorelin (hexarelin; EP-23905, MF-6003) Ipamorelin (NNC 26-0161) Relamorelin (RM-131, BIM-28131, BIM-28163) Tabimorelin (NN-703)
The UN has to protect against any kind of human rights violation, and in the UN system, some specialized agencies, like ILO and United Nations High Commissioner for Refugees (UNHCR), work in the human rights' protection fields. The UN agency, ILO, is trying to end any kind of discrimination in the work field and child labor; after that, this agency promotes fundamental labor rights and to get safe and secure for the laborers. United Nations Environment Programme (UNEP) is one of the UN's (United Nations) agencies and is an international organization that coordinates UN activities on the environment.
Weak central coherence theory hypothesizes that a limited ability to see the big picture underlies the central disturbance in autism. One strength of this theory is predicting special talents and peaks in performance in autistic people. Another theory, enhanced perceptual functioning, focuses more on the superiority of locally oriented and perceptual operations in autistic individuals. Yet another theory, monotropism, posits that autism stems from a different cognitive style, tending to focus attention and processing resources intensely, to the exclusion of other stimuli. These theories map well from the underconnectivity theory of autism.
=== Airglow of the Earth === The Earth's night sky is illuminated by diffuse light, called airglow, that is produced by radiative transitions of atoms and molecules. Among the most intense such features observed in the Earth's night sky is a group of infrared transitions at wavelengths between 700 nanometers and 900 nanometers. In 1950, Aden Meinel showed that these were transitions of the hydroxyl molecule, OH.
=== Livestock and crop predation === A limitation of food sources in early spring and wild berry and nut crop failures in summer may contribute to bears regularly feeding from human-based food sources. These bears often eat crops, especially during autumn hyperphagia when natural foods are scarce. Favored crops include apples, oats and corn. American black bears can do extensive damage in areas of the northwestern United States by stripping the bark from trees and feeding on the cambium. Livestock depredations occur mostly in spring. Although they occasionally hunt adult cattle and horses, they seem to prefer smaller prey such as sheep, goats, pigs and young calves. They usually kill by biting the neck and shoulders, though they may break the neck or back of the prey with blows with the paws. Evidence of a bear attack includes claw marks and is often found on the neck, back and shoulders of larger animals. Surplus killing of sheep and goats is common. American black bears have been known to frighten livestock herds over cliffs, causing injuries and death to many animals; whether this is intentional is not known. Occasionally bears kill pets, especially domestic dogs, which are most prone to harass a bear. It is not recommended to use unleashed dogs to deter bear attacks. Although large, aggressive dogs can sometimes cause a bear to run, if pressed, angry bears often turn the tables and end up chasing the dogs in return. A bear in pursuit of a pet dog can threaten both canid and human lives.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.